Tuesday October 26, 2004
Adult Stem Cells from Human Retina Reproduce and Differentiate Easily
No Problems with Tumor Formation says Researcher
TORONTO/LAUSANNE, October 26, 2004 (LifeSiteNews.com) - A stem cell researcher was ‘beyond shock’ at how easily stem cells taken from eyes reproduced in the lab. “Within seven days, they go from one cell to 7,000 to 10,000 cells,” says Brenda Coles of the University of Toronto, lead author of a report in the Proceedings of the National Academy of Sciences. Researchers from Toronto and Lausanne, Switzerland discovered that retinal cells were easy to obtain and the results of the tests on mice and chickens offer hope for curing certain types of blindness.
The cells were transplanted into the eyes of mice and embryonic chick eyes. The cells reproduced and were able to survive, migrate, integrate, and differentiate into all seven types of retinal tissue, especially as photoreceptors. The experiment suggests that human retinal stem cells eventually may be valuable in treating human retinal diseases such as macular degeneration and retinitis pigmentosa.
The mice and chick eyes “look perfectly normal,” says Coles. The next step of the research will be to see if blind mice can have their sight restored by the stem cell treatment. After more animal tests the research could move on to human testing, but will probably take another decade, the researchers say.
The current tests, published Monday, show promise especially since the animals had no problems with the cells reproducing uncontrollably, a common problem with embryo stem cell treatment. “They didn't take over the eye, or cause any cancerous-type things or sit in inappropriate places,” says Coles. “They found their home and responded to the proper signals.”
ph
Latest Headlines
- Irony: 19-Child Duggar Family Renting Former Home of Local Planned Parenthood Leader

- Document Reveals Inconsistencies in ND's Jenkins Claims on ND88

- New Country Music Star Born as Pro-Life Ballad Climbs the Charts

- Future of Pontifical Academy for Life at Stake as Members Meet in Closed Door Session

- Rally Planned in Defence of Canadian Pro-Life Ad

- Commentary on February 8 News

- Chinese Human-Rights Crusaders Nominated for Nobel Peace Prize

- U.K.’s Conservative Leader Pledges Full Support to Gay Agenda

- B.C. Civil Liberties Association Goes to Bat for Pro-Life Student Club

- Police Refuse to Release Federal "Threat Assessment" on Wis. Pro-Lifers

- Canadian Human Rights Commission Appeals Ruling against Hate Messages Statute

- Homosexual Activist Keith Norton Dies at 69

- Malta Celebrates 32nd Pro-Life Day

- My Vote for Best Pro-life Super Bowl Ad: Google’s Parisian Love Story

- Pope: Family Necessary for Child Development

- Letters to the Editor

Most Read this Week
- Veterans, Former Army Legal Chief Defend “Don’t Ask, Don’t Tell”
- Planned Parenthood President Lands Spot on Ford Foundation Board
- Rabbis Warn against 'Disaster' of Open Homosexuality in the Military
- Football Pros Give Support to Tim Tebow Super Bowl Ad
- Clash of the Abortion Titans: Planned Parenthood Launches 'Pro-Choice' Football Ad
- Canadian Station Pulls Pro-Life Ad – Too “Graphic”
- Hijacking the Brain — How Pornography Works
- Group Exposes Media "Fraud" at March for Life
- U.S. Sisters in Crisis after Embracing “Secular Culture”: Vatican Cardinal
- NYT: Rampant Polygamy in Gay 'Marriage' May Benefit Institution
MORE NEWS:
LifeSiteNews.com Home Page
Last 10 Days
Archives
Special Reports
Copyright © LifeSiteNews.com. This work is licensed under a Creative Commons Attribution-No Derivatives License. You may republish this article or portions of it without request provided the content is not altered and it is clearly attributed to "LifeSiteNews.com". Any website publishing of complete or large portions of original LifeSiteNews articles MUST additionally include a live link to www.LifeSiteNews.com. The link is not required for excerpts. Republishing of articles on LifeSiteNews.com from other sources as noted is subject to the conditions of those sources.








Back to Top